Tianjin Tianyao Pharmaceuticals Co Ltd - Asset Resilience Ratio
Tianjin Tianyao Pharmaceuticals Co Ltd (600488) has an Asset Resilience Ratio of 0.00% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Tianjin Tianyao Pharmaceuticals Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2015)
This chart shows how Tianjin Tianyao Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. See 600488 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Tianjin Tianyao Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600488 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥128.80K | 0.0% |
| Total Liquid Assets | CN¥128.80K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Tianjin Tianyao Pharmaceuticals Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tianjin Tianyao Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tianjin Tianyao Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Tianjin Tianyao Pharmaceuticals Co Ltd (2001–2015)
The table below shows the annual Asset Resilience Ratio data for Tianjin Tianyao Pharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2015-12-31 | 4.95% | CN¥150.00 Million ≈ $21.95 Million |
CN¥3.03 Billion ≈ $443.85 Million |
+4.90pp |
| 2003-12-31 | 0.05% | CN¥758.82K ≈ $111.04K |
CN¥1.60 Billion ≈ $234.85 Million |
-17.21pp |
| 2002-12-31 | 17.26% | CN¥244.90 Million ≈ $35.84 Million |
CN¥1.42 Billion ≈ $207.65 Million |
+2.70pp |
| 2001-12-31 | 14.55% | CN¥165.06 Million ≈ $24.15 Million |
CN¥1.13 Billion ≈ $165.94 Million |
-- |
About Tianjin Tianyao Pharmaceuticals Co Ltd
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid r… Read more